Fig. 6From: The Amyloidosis Forum: a public private partnership to advance drug development in AL amyloidosisClinical Trial Endpoints. Overview of established hematologic response criteria and target organs to measure responses to treatment in relation to established objective endpoints and the identified need for novel endpoints to enable early and robust trial readoutsBack to article page